Copyright 2009 Medical News Today Latest Clinical Trials / Drug Trials News From Medical News Today. http://www.medicalnewstoday.com/sections/clinical_trials/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Fri, 20 Nov 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/171708.php http://www.medicalnewstoday.com/articles/171708.php A protein found in the saliva of ticks helps protect mice from developing Lyme disease, Yale researchers have discovered. The findings, published in the November 19 issue of Cell Host & Microbe, may spur development of a new vaccine against infection from Lyme disease, which is spread through tick bites. Traditionally, vaccines have directly targeted specific pathogens. Infectious Diseases / Bacteria / Viruses Fri, 20 Nov 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/171727.php http://www.medicalnewstoday.com/articles/171727.php Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII), announces the first patient enrollment in its prospective, randomized CALCIUM 360° clinical trial, part of the company's 360° Clinical Series. The CALCIUM 360° study will evaluate the treatment of peripheral arterial disease (PAD) behind and below the knee using CSI's Diamondback 360® PAD System, a minimally invasive catheter for treating PAD anywhere in the leg. The first procedure was performed successfully by Dr. Cardiovascular / Cardiology Fri, 20 Nov 2009 05:00:00 PST http://www.medicalnewstoday.com/articles/171728.php http://www.medicalnewstoday.com/articles/171728.php Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, announced the commencement of its IL-4 receptor alpha inhibitor bronchoprovocation trial. Study AIR645-CS2 is a phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of inhaled AIR645 in suppressing the asthmatic response in subjects with mild asthma. Respiratory / Asthma Fri, 20 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/171601.php http://www.medicalnewstoday.com/articles/171601.php Afexa Life Sciences Inc. ("Afexa" or the "Company") (TSX:FXA) maker of COLD-FX announced the launch of a pilot clinical trial of a new formulation, LIP-01 that has shown promise in reducing blood lipids - including cholesterol. Cholesterol can stick to the walls of arteries, causing atherosclerosis or "hardening of the arteries." This, in turn, can ultimately lead to a heart attack or stroke. Cholesterol Fri, 20 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/171603.php http://www.medicalnewstoday.com/articles/171603.php Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that enrollment has been completed for the first of three cohorts of patients receiving DV-601 hepatitis B therapy in a Phase 1b clinical trial. The safety profile of patients in the first cohort met pre-specified criteria for dose escalation and the second cohort has been opened for enrollment. Dynavax expects to report top-line data from this trial in the second half of 2010. Liver Disease / Hepatitis Fri, 20 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/171608.php http://www.medicalnewstoday.com/articles/171608.php Immunization with either live attenuated influenza vaccine (LAIV, also known as FluMist®), or trivalent inactivated influenza vaccine (TIV), appears to offer a protection (~ 45%) against the novel A/H1N1 virus, the cause of the present influenza pandemic. However, the benefit was largely attributed to the youngest age group. The finding emerges from an evaluation of medical encounters and seasonal influenza immunization of U.S. military service members. Swine Flu Fri, 20 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/171609.php http://www.medicalnewstoday.com/articles/171609.php nContact Surgical, Inc. ("nContact"), a leader in the investigation of devices for minimally-invasive treatment for heart conditions, announced that data from a poster was presented at the American Heart Association Scientific Sessions in Orlando. The study demonstrated that the convergent approach, which combines surgical and electrophysiological expertise, appears to be a good strategy to achieve short term success in patients with long standing persistent atrial fibrillation (AF). Heart Disease Fri, 20 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/171610.php http://www.medicalnewstoday.com/articles/171610.php Curemark LLC, a drug research and development company focused on the treatment of neurological diseases, announced that the company has begun enrolling patients in Phase III clinical trials for CM-AT, its autism treatment, at three additional clinical trial sites. Autism Fri, 20 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/171611.php http://www.medicalnewstoday.com/articles/171611.php Accumetrics, Inc., developer of the VerifyNow System, the first point-of-care method for measuring platelet reactivity, announces that its market-leading VerifyNow P2Y12 Test was one of multiple methods evaluated in the POPular study, which was presented during a Late Breaking Clinical Trials session at the American Heart Association's annual Scientific Sessions. Cardiovascular / Cardiology Fri, 20 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/171612.php http://www.medicalnewstoday.com/articles/171612.php Adamas Pharmaceuticals, Inc., a privately held company, announced that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. Swine Flu Fri, 20 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/171613.php http://www.medicalnewstoday.com/articles/171613.php Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System for transdermal drug delivery, today announced positive results of a clinical study of its Symphony tCGM System in patients with Type 1 and Type 2 Diabetes. Diabetes Fri, 20 Nov 2009 02:00:00 PST http://www.medicalnewstoday.com/articles/171614.php http://www.medicalnewstoday.com/articles/171614.php AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point. Alzheimer's / Dementia Fri, 20 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/171577.php http://www.medicalnewstoday.com/articles/171577.php For years, it has been widely assumed that older adults may experience memory loss and other cognitive problems following surgery. But a new study from researchers at Washington University School of Medicine in St. Louis questions those assumptions. In fact, the researchers were not able to detect any long-term cognitive declines attributable to surgery in a group of 575 patients they studied. Alzheimer's / Dementia Fri, 20 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/171587.php http://www.medicalnewstoday.com/articles/171587.php Genzyme Corporation (Nasdaq: GENZ) reported results of a phase 2/3 study of its advanced phosphate binder (APB). The trial met its primary endpoint, which was to show that the APB lowered phosphate levels effectively compared to placebo. However, the APB did not show a significant improvement in phosphate lowering compared to Genzyme's Renvela® (sevelamer carbonate). Based on these results, the company is not planning to pursue further clinical development of the APB. GastroIntestinal / Gastroenterology Fri, 20 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/171588.php http://www.medicalnewstoday.com/articles/171588.php Why do some smokers develop lung disease and others don't? And just how effective is supplemental oxygen therapy in treating patients with emphysema? The University of Michigan Health System will try to find out, through two new multi-center research studies that seek to improve diagnosis and treatment for millions of people affected by emphysema, chronic bronchitis and other lung diseases. Together, those conditions are known as chronic obstructive pulmonary disease (COPD). Respiratory / Asthma Fri, 20 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/171590.php http://www.medicalnewstoday.com/articles/171590.php Clinical Data, Inc. (NASDAQ: CLDA) announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze™, a potential best-in-class vasodilator for use in cardiac stress testing. The study will evaluate the safety and efficacy of Stedivaze (apadenoson) for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI), a method for detecting defects in the blood supply to the heart. Cardiovascular / Cardiology Fri, 20 Nov 2009 01:00:00 PST http://www.medicalnewstoday.com/articles/171596.php http://www.medicalnewstoday.com/articles/171596.php At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). Results of the double-blind treatment phase of this study, which enrolled patients from the U.S. Erectile Dysfunction / Premature Ejaculation Fri, 20 Nov 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/171560.php http://www.medicalnewstoday.com/articles/171560.php Beth Israel Deaconess Medical Center (BIDMC) neurologists Alvaro Pascual-Leone, MD, PhD, and Daniel Tarsy, MD, have been awarded grants totaling more than $1.5 million from the Michael J. Fox Foundation for Parkinson's Research (MJFF) to conduct investigations aimed at improving the quality of life for patients with Parkinson's disease. Parkinson's Disease Fri, 20 Nov 2009 00:00:00 PST http://www.medicalnewstoday.com/articles/171566.php http://www.medicalnewstoday.com/articles/171566.php Patients coping with the chaos and misery of Borderline Personality Disorder now have reason for strong confidence in making major life changes through a new treatment, Schema Therapy. For the first time, three major outcome studies have shown that many patients with Borderline Personality Disorder can achieve full recovery across the complete range of symptoms. Psychology / Psychiatry Thu, 19 Nov 2009 23:00:00 PST http://www.medicalnewstoday.com/articles/171561.php http://www.medicalnewstoday.com/articles/171561.php Exelixis, Inc. (Nasdaq:EXEL) reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors. XL147 is a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy. Cancer / Oncology Thu, 19 Nov 2009 18:00:00 PST http://www.medicalnewstoday.com/articles/171551.php http://www.medicalnewstoday.com/articles/171551.php ImmuPharma PLC (LSE:IMM) the specialist discovery and development pharmaceutical company is pleased to announce the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care. Lupus Thu, 19 Nov 2009 14:00:00 PST http://www.medicalnewstoday.com/articles/171538.php http://www.medicalnewstoday.com/articles/171538.php New data from a 6-month open label randomised controlled trial show INVEGA® (paliperidone ER) is associated with significantly less metabolic effects compared to oral olanzapine in people with schizophrenia, while demonstrating comparable efficacy.1 The results were presented at the 15th Biennial Winter Workshop in Psychoses in Barcelona, Spain. Schizophrenia Thu, 19 Nov 2009 06:00:00 PST http://www.medicalnewstoday.com/articles/171567.php http://www.medicalnewstoday.com/articles/171567.php Millennium: The Takeda Oncology Company announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company's second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March. MLN9708 is the third molecule Millennium has developed from its innovative research in protein homeostasis. Lymphoma / Leukemia / Myeloma Thu, 19 Nov 2009 06:00:00 PST http://www.medicalnewstoday.com/articles/171571.php http://www.medicalnewstoday.com/articles/171571.php CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer. CytRx President and CEO Steven A. Kriegsman said, "This planned clinical trial is a key step forward in our plans to build a commercial oncology franchise for CytRx. Cancer / Oncology Thu, 19 Nov 2009 03:00:00 PST http://www.medicalnewstoday.com/articles/171452.php http://www.medicalnewstoday.com/articles/171452.php Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED). The multi-center study conducted in Korea was a randomized, double-blind, placebo-controlled study, designed to investigate the efficacy and safety of udenafil in patients with ED. Erectile Dysfunction / Premature Ejaculation